Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease (Q33798966)

29 July 2017

Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease (English)

1 reference

29 July 2017

1 reference

Hasan S Jafri

6

0 references

Asuncion Mejias

object named as

Asuncion Mejias

3

0 references

Lynn Mahony

4

object named as

Lynn Mahony

1 reference

29 July 2017

12

Edmund V Capparelli

1 reference

29 July 2017

Jane C Burns

1

1 reference

29 July 2017

Brookie M Best

2

1 reference

29 July 2017

David E Fixler

5

1 reference

29 July 2017

Marian E Melish

7

1 reference

29 July 2017

Mary Anne Jackson

8

1 reference

29 July 2017

Basim I Asmar

9

1 reference

29 July 2017

David J Lang

10

1 reference

29 July 2017

James D Connor

11

1 reference

29 July 2017

Monica L Keen

13

1 reference

29 July 2017

Khalid Mamun

14

1 reference

29 July 2017

Gregory F Keenan

15

1 reference

29 July 2017

Octavio Ramilo

16

1 reference

29 July 2017

language of work or name

English

0 references

publication date

30 July 2008

1 reference

The Journal of Pediatrics

29 July 2017

1 reference

29 July 2017

153

1 reference

29 July 2017

833-838

1 reference

29 July 2017

6

1 reference

Efficacy of infliximab in long-lasting refractory Kawasaki disease

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

The effect of TNFalpha blockade in complicated, refractory Kawasaki disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

Infliximab treatment for refractory Kawasaki syndrome

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

Diagnosis, treatment, and long-term management of Kawasaki disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

Infliximab as a novel therapy for refractory Kawasaki disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

Gamma globulin re-treatment in Kawasaki disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

TNF induces internalization of the p60 receptor and shedding of the p80 receptor

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

Serious liver disease induced by infliximab

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856847

Infliximab for Kawasaki syndrome

30 October 2018

1 reference

12 December 2020

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group

1 reference

12 December 2020

10.1016/J.JPEDS.2008.06.011

Identifiers

DOI

1 reference

29 July 2017

1 reference

29 July 2017

1 reference